Loading...

COLL COLLEGIUM PHARMACEUTICAL INC US FDA Inspections 8-K Filing

CLLG

CLL

COLLEGIUM PHARMACEUTICAL INC

(COLL)

2024 8-K

Show Summary

Summary

Management Change

Board Expansion

2025 Financial Guidance

Merger Announcement

CEO Appointment

Merger Completion

Earnings Reports

Merger Agreement and Loan A...

FDA Exclusivity Granted

Appointment, Separation Agr...

Annual Meeting Voting Results

Share Repurchase Agreement

Management Change

Earnings Reports

Authorized Generic Agreement

Redemption of Convertible S...

Earnings Reports

Press Release and Investor ...

Share Repurchase Agreement

FDA Exclusivity Grant

Share Repurchase Agreement

Earnings Reports

Earnings Reports

Financial Results Announcement

Material Definitive Agreement

Earnings Reports

Press Release and Share Rep...

External Links:

Collegium Pharmaceutical, Inc. announces FDA granting pediatric exclusivity for Nucynta and Nucynta ER, extending exclusivity of the Nucynta Franchise.

AI Assistant

COLLEGIUM PHARMACEUTICAL INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.